The development of a clinical prediction model for response to methotrexate, tofacitinib, and etanercept in patients with Psoriatic Arthritis.

ABSTRACT:

Background

The aim of this study was to use clinical data to develop a prediction model for treatment response, comparing tofacitinib to methotrexate or etanercept in individual patients with Psoriatic Arthritis.

Methods

Data from the development cohort (n = 80) of the TOFA-PREDICT trial were used. The cohort included PsA patients naïve to disease-modifying antirheumatic drugs (DMARDs) randomised to tofacitinib (n = 20) or methotrexate (n = 20), and patients failing conventional synthetic DMARD (csDMARD) treatment randomised to add-on tofacitinib (n = 20) or etanercept (n = 20). Treatment response was defined as achievement of minimal disease activity at week 16. Elastic net regression was used to select relevant baseline predictors in the complete cohort and in treatment su

SUBMITTER: Perton FT 

PROVIDER: S-EPMC12560565 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature